ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

J&J, Bayer Face More Lawsuits from Possible Xarelto-Related Deaths

lawsuits filed

More people whose family members died after taking the blood thinner Xarelto recently filed lawsuits against Johnson & Johnson and Bayer, claiming the drug caused irreversible bleeding and led to the deaths.

The most recent claims, filed in New York, Vermont and Florida, blame J&J and Bayer for failing to warn healthcare professionals and patients of the dangers of uncontrolled bleeding caused by Xarelto. The drug has no antidote to stop potentially fatal bleeding, a fact plaintiffs say the drug companies didn’t publicize.

The drug companies spent millions marketing the blockbuster drug as convenient and effective. Patients flocked to Xarelto (rivaroxaban) in part because it does not require blood tests and has a one-size-fits-all approach to dosing, unlike the decades old drug warfarin (Coumadin), which requires dietary restrictions and routine blood work. Patients even paid an increased price for the new medication, $3,000 a year, vs. warfarin’s annual cost of $200.

Like millions of other Americans and others around the world, the plaintiffs in these lawsuits took the new anticoagulant to prevent stroke and other cardiovascular health problems – adding to the billions brought in by the drug. According to the lawsuits, instead of preventing these problems, patients ended up suffering bleeding which led to a number of complications, pain, suffering and ultimately, death.

New Claims: Patients Weren’t Warned about Fatal Bleeding Risks

“Defendants’ boxed warning did not address the increased risk for serious and fatal bleeding, despite the fact that the information listed on their website . . . states that in comparison to warfarin, patients have more gastrointestinal bleeds and need more transfusions,” states one of the complaints filed in Florida.

The trio of lawsuits is the latest among the mounting bleeding cases against the drugmakers. Lawyers expect more injured people or family members to come forward with additional claims.

According to the complaints, defendants mislead the public into thinking rivaroxaban was safe. The drug is associated with rectal, intestinal and abdominal bleeding as well as hemorrhaging in the brain, and the complaints say plaintiffs were exposed to these “serious and dangerous side effects.”

Blood thinners as a class are considered dangerous, but plaintiffs say Xarelto is more dangerous than others in its class, according to data filed in the complaints.

“In the first quarter of 2013, the number of reported serious adverse events associated with Xarelto (680) overtook that of Pradaxa (528)…which had previously ranked as the number one,” one complaint read.

A German study mentioned in the complaints said regulators received nearly 1,000 reports of adverse events, including 72 deaths, ­ more than those attached to warfarin.

Because the drug lacks an antidote, it can take up to 24 hours to leave the system. In the elderly, the main target group for this drug, it can take longer and Xarelto can be especially dangerous.

In fact, the deceased plaintiff from New York was an older man who used the drug from May 2013 to August 2013 before he suffered uncontrollable bleeding. He sustained “severe and permanent personal injuries, pain, suffering and emotional distress” before ultimately succumbing to sudden death in December of the same year.

Claims assert that if plaintiffs and their doctors had known of the dangers, they would never have used the drug.

Did Defendants Fail to Inform the Public?

The complaints’ list of failures on the part of the defendants is a long one.

According to the plaintiffs, J&J, Janssen and Bayer failed to:

  • Fully study and research Xarelto’s safety
  • Provide adequate warnings about safety risks
  • Warn that the degree or extent of anticoagulation is different in each patient
  • Warn that there is no antidote
  • Include a boxed warning about uncontrollable bleeding

Plaintiffs also accuse the drug companies of willfully endangering patients by withholding information about the risks even if they already knew of the dangers.

“Defendants ignored the association between the use of Xarelto and the risk of developing life-threatening bleeding,” according to a complaint filed in Vermont by a daughter who lost her father. “Defendants had a duty to exercise reasonable care . . . including duty to assure that the product would not cause users to suffer unreasonable, dangerous side effects.”

The two pharmaceutical giants are no strangers to legal issues. Bayer paid out hundreds of millions to settle lawsuits related to Yaz, its birth control pill, and J&J faces thousands of lawsuits related to its DePuy ASR and Pinnacle hip implants as well as thousands more for transvaginal mesh implants.

The claims made against Xarelto come in the wake of thousands of lawsuits against another blood thinner, Pradaxa. Pradaxa manufacturer Boehringer Ingelheim ended many of the claims against it with a $650 million settlement earlier this year.

Michelle Llamas, Senior Content Writer
Written By Michelle Llamas Senior Writer

Michelle Llamas has been writing articles and producing podcasts about drugs, medical devices and the FDA for nearly a decade. She focuses on various medical conditions, health policy, COVID-19, LGBTQ health, mental health and women’s health issues. Michelle collaborates with experts, including board-certified doctors, patients and advocates, to provide trusted health information to the public. Some of her qualifications include:

  • Member of American Medical Writers Association (AMWA) and former Engage Committee and Membership Committee member
  • Centers for Disease Control and Prevention (CDC) Health Literacy certificates
  • Original works published or cited in The Lancet, British Journal of Clinical Pharmacology and the Journal for Palliative Medicine

3 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. McGowan v. Janssen Research & Development et al. (2014, July 25). U.S. District Court District of Vermont. Case No. 2:14-cv-00159-cr. Retrieved from
  2. Packard v. Janssen Research & Development et al. (2014, June23). U.S. District Court for the Southern District of Florida. Case No. 1:14-cv-61448-JAL. Retrieved from
  3. Griggs v. Janssen Research & Development et al. (2014, August 14). U.S. District Court Eastern District of New York. Case No. 1:14-cv-04841-FB-VMS. Retrieved from
View All Sources
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's trusted legal partners support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(888) 645-1617